Compare GEVO & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GEVO | MYGN |
|---|---|---|
| Founded | 2005 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 421.1M | 444.2M |
| IPO Year | 2010 | 1996 |
| Metric | GEVO | MYGN |
|---|---|---|
| Price | $1.53 | $4.55 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 7 |
| Target Price | $6.58 | ★ $7.64 |
| AVG Volume (30 Days) | ★ 2.9M | 1.4M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.82 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $711,000.00 | ★ $771,400,000.00 |
| Revenue This Year | $19.44 | $6.86 |
| Revenue Next Year | $5.59 | $5.45 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 2.33 |
| 52 Week Low | $1.12 | $3.53 |
| 52 Week High | $2.97 | $8.59 |
| Indicator | GEVO | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 39.42 | 54.92 |
| Support Level | N/A | $4.31 |
| Resistance Level | $1.93 | $4.92 |
| Average True Range (ATR) | 0.09 | 0.30 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 30.39 | 67.30 |
Gevo Inc is a growth-oriented company that focuses on hard to decarbonize market sectors such as jet fuel, certain specialty fuels, on-road fuels, chemicals and materials, and certain products for the food chain such as protein and feeds made as co-products from its processes. It produces and sells competitively priced, renewable, drop-in products for these sectors, and generate carbon abatement value through its plant design and business systems. It owns and operates an ethanol plant with an adjacent CCS facility, Class VI carbon-storage well, and others. The group is currently developing the world's first large-scale ATJ facility to be co-located at the North Dakota site.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.